Information about COVID 19

Monovalent MRNA COVID-19 Vaccines Update September 2023

The FDA granted approvals and emergency use authorizations to updated Moderna and Pfizer Covid- 19 vaccines. These updated 2023-24 formulations are monovalent (including one viral strain), designed to target the XBB.1.5 Omicron strain and to protect against serious consequences of this and other cross-reactive circulating SARS-CoV-2 variants.



Bivalent (two viral strain) Moderna and Pfizer-BioNTech COVID-19 vaccines are no longer authorized in the U.S.

Monovalent COVID-19 vaccines for individuals 12 years of age and older are now FDA-approved and marketed as commercial products.

Pfizer-BioNTech – COMIRNATY® : Package Insert:

Moderna – SPIKEVAX® – Package Insert:

Individuals 5 years of age and older regardless of previous vaccination are eligible to receive a single dose of an updated mRNA COVID-19 vaccine at least 2 months since the last dose of any COVID-19 vaccine. Please refer to the CDC’s Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States for additional clinical information and recommendations:

Per a CDC Health Alert Network memo, providers may simultaneously administer COVID-19, influenza, and respiratory syncytial virus (RSV) vaccines to eligible patients. Different anatomic sites should be used for vaccine administration (e.g., injections in same limb separated by at least 1 inch; high-dose influenza vaccines given in different limb).